Quote:
Originally Posted by RWebb
I meant the stock yes. I always like the guy that sells shovels to the miners...
Illumina was great for a while...
|
Yeah but a shovel company has to have revenues and then won’t get a 100X revenue multiple or get taken out at 2X premium. And there are a lot fewer shovel companies than miners, and a lot fewer varieties of shovels to make than places to dig. Hence there’s only been a few ILMNs whereas there’s dozens of new MRNAs every year.
Honestly I think what the world needs more than any new drug is effective blood or urine screening for cancer. And there are interesting little companies trying to do it. If they succeed, they might get to $5-10BN market cap. A wing and prayer biotech can get to $5BN on some press releases and in vitro data. Get something cool to phase 3 and you’re $10BN. Actually get a good drug approved, or develop a “platform”, and $20-40BN. Meanwhile the cancer screening company that is actually saving lives instead of merely extending survival is plugging along in small cap land. It ain’t fair, but oh well.